Linda Marban & Paragon Therapeutics
3 shared events · Importance 3 · Last updated Sep 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Linda Marban: CEO who made positive statements about Deramiocel; now named in securities fraud lawsuits.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
Regulatory
Linda Marban: Linda Marban, CEO of Paragon Therapeutics, expressed confidence in the evidence supporting Deramiocel and emphasized the company's commitment to bringing the therapy to patients.
Paragon Therapeutics: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
Regulatory
Linda Marban: Capricor's CEO, whose positive statements about HOPE-3 and Deramiocel are cited in the complaint as materially misleading.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Linda Marban and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard